.Pharmacolibrary.Drugs.ATC.J.J05AF10 .Pharmacolibrary.Drugs.ATC.J.J05AF10| name: | Entecavir | |
| ATC code: | J05AF10 | route: | oral |
| compartments: | 2 | |
| dosage: | 0.5 | mg |
| volume of distribution: | 76 | L |
| clearance: | 14 | L/h |
| other parameters in model implementation | ||
Entecavir is a nucleoside analogue with potent and selective activity against hepatitis B virus (HBV). It inhibits the HBV DNA polymerase, reducing viral replication. It is approved for the treatment of chronic hepatitis B infection in adults and pediatric patients over 2 years of age.
Pharmacokinetic parameters reported for healthy adult subjects following single oral administration.
Yoshitsugu, H, et al., & Hiraoka, M (2011). Pooled model-based approach to compare the pharmacokinetics of entecavir between Japanese and non-Japanese chronic hepatitis B patients. Diagnostic microbiology and infectious disease 70(1) 91–100. DOI:10.1016/j.diagmicrobio.2010.12.009 PUBMED:https://pubmed.ncbi.nlm.nih.gov/21513847
Zhu, M, et al., & Pfister, M (2008). Lack of an effect of human immunodeficiency virus coinfection on the pharmacokinetics of entecavir in hepatitis B virus-infected patients. Antimicrobial agents and chemotherapy 52(8) 2836–2841. DOI:10.1128/AAC.01366-07 PUBMED:https://pubmed.ncbi.nlm.nih.gov/18391039